Senseonics

By Dave Muoio November 1, 2017
Implantable continuous glucose monitor (CGM) maker Senseonics is still making the long trudge toward FDA clearance, but at least the company has plenty of European activity to keep it occupied in the meantime. On a Q3 earnings call, CEO Timothy Goodnow shared details on his company’s continued ramp-ups and rollouts across Europe, its first entry into an international market, and the receipt of a...
By Jonah Comstock September 13, 2017
Today was a big day in the world of diabetes management technology, with major announcements from Abbott, Livongo, and Senseonics. Read on below for a round-up of diabetes news. Livongo acquires Diabeto Mountain View, California-based Livongo Health, the chronic condition management technology company founded by former Allscripts CEO Glen Tullman, has acquired Diabeto, a diabetes management...
By Jonah Comstock August 11, 2017
As implantable CGM company Senseonics continues to wait for clearance from the FDA, the company isn't sitting on its hands. On a Q2 earnings call, CEO Tim Goodnow reported that the company continues to expand its operations in Europe, is close to a CE Mark for a longer-lasting second generation device, and is partnering with Roche and Type Zero on an artificial pancreas study with an eye on...
By Jonah Comstock July 25, 2017
Senseonics and TypeZero's R&D partnership around the artificial pancreas is leveling up. The two organizations announced today that they would team up with pharmaceutical and medical device company Roche to launch three European clinical trials of their combined closed-loop system. The research is backed by the National Institutes of Health (NIH) through its International Diabetes Closed Loop...
By Heather Mack May 12, 2017
Virtual medical assistant company Sensely is collaborating with the Mayo Clinic to ascertain how to leverage patient engagement and chronic disease monitoring technology. The partnership will blend the Mayo Clinic’s triage algorithms and clinical expertise with Sensely’s patient engagement platform in hopes of assessing and predicting which resources can be best used at the right time to help...
By Jonah Comstock May 12, 2017
A new partnership in the diabetes space could bring the promise of an artificial pancreas closer to reality. Senseonics, a Germantown, Maryland company working on a pill-sized, implantable continuous glucose monitor that can last 90 days without needing replacement, will work with digital, personalized medicine company TypeZero Technologies on a project to integrate readings from Senseonics...
By Heather Mack May 5, 2017
Germantown, Maryland-based Senseonics may not be rolling in profits, but the company – which is working towards commercializing its implantable, long-term continuous glucose monitor – isn’t holding back on characterizing their position as strong. With expanded commercial launches in Germany and Sweden, plans for a presence in eight European countries by mid-2017, a CE Mark for their second...
By Jonah Comstock March 3, 2017
Implantable longterm continuous glucose monitor company Senseonics is in a better place than its financials would suggest. The company posted a net loss of $9.9 million last quarter, up from an $8.4 million loss in the year prior, and is planning to borrow about $5 million from the Oxford Silicon Valley Bank that it’s already $20 million in debt to. But Senseonic’s potentially game-changing...
By Heather Mack December 7, 2016
Madison, Wisconsin-based Propeller Health, which offers a digitally-guided respiratory therapy platform, has teamed up with Medical International Research (MIR) to offer several of the Italian health technology company’s mobile and clinical spirometers alongside the Propeller system. The addition of sprirometers will give Propeller a more complete vision of the people using their platform, which...
By Heather Mack December 2, 2016
Germantown, Maryland-based Senseonics, which is working on a long-term implantable continuous glucose monitor called Eversense, has expanded its exclusive distribution agreement with Roche. Now, Roche will have exclusive rights to promote, market and sell the Eversense product line to diabetes clinics and patients in in most of Europe (excluding Scandinavia and Finland), the Middle East (except...